Design of a prospective patient‐level pooled analysis of two parallel trials of empagliflozin in patients with established heart failure

Role of Impaired Nutrient and Oxygen Deprivation Signaling and Deficient Autophagic Flux in Diabetic CKD Development: Implications for Understanding the Effects of Sodium-Glucose Cotransporter 2-Inhibitors

(2020) Milton Packer   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Totality of evidence in trials of sodium–glucose co-transporter-2 inhibitors in the patients with heart failure with reduced ejection fraction: implications for clinical practice

(2020) Javed Butler et al.   EUROPEAN HEART JOURNAL

EMPEROR ‐Reduced: confirming sodium–glucose co‐transporter 2 inhibitors as an essential treatment for patients with heart failure with reduced ejection fraction

(2020) John J.V. McMurray   EUROPEAN JOURNAL OF HEART FAILURE

SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials

(2020) Faiez Zannad et al.   LANCET

Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure

(2020) Milton Packer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dapagliflozin in Patients with Chronic Kidney Disease

(2020) Hiddo J.L. Heerspink et al.   NEW ENGLAND JOURNAL OF MEDICINE

Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure

(2020) Deepak L. Bhatt et al.   NEW ENGLAND JOURNAL OF MEDICINE

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy

(2019) Vlado Perkovic et al.   NEW ENGLAND JOURNAL OF MEDICINE

Evaluation of the effect of sodium–glucose co‐transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR‐Reduced trial

(2019) Milton Packer et al.   EUROPEAN JOURNAL OF HEART FAILURE

Evaluation of the effects of sodium–glucose co‐transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR‐Preserved Trial

(2019) Stefan D. Anker et al.   EUROPEAN JOURNAL OF HEART FAILURE

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction

(2019) John J.V. McMurray et al.   NEW ENGLAND JOURNAL OF MEDICINE

SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis

(2019) Brendon L Neuen et al.   Lancet Diabetes & Endocrinology

Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE–TIMI 58 randomised trial

(2019) Ofri Mosenzon et al.   Lancet Diabetes & Endocrinology

SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials

(2018) Thomas A Zelniker et al.   LANCET

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

(2017) Bruce Neal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes

(2016) Christoph Wanner et al.   NEW ENGLAND JOURNAL OF MEDICINE

Assessing the consistency assumption by exploring treatment by covariate interactions in mixed treatment comparison meta-analysis: individual patient-level covariates versus aggregate trial-level covariates

(2012) Sarah Donegan et al.   STATISTICS IN MEDICINE